Madrigal Pharmaceuticals (MDGL) EBIAT (2019 - 2025)
Historic EBIAT for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$114.2 million.
- Madrigal Pharmaceuticals' EBIAT fell 675.55% to -$114.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$289.1 million, marking a year-over-year increase of 4425.49%. This contributed to the annual value of -$465.9 million for FY2024, which is 2469.56% down from last year.
- According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' EBIAT is -$114.2 million, which was down 675.55% from -$42.3 million recorded in Q2 2025.
- Madrigal Pharmaceuticals' EBIAT's 5-year high stood at -$42.3 million during Q2 2025, with a 5-year trough of -$152.0 million in Q2 2024.
- Moreover, its 5-year median value for EBIAT was -$76.9 million (2023), whereas its average is -$84.5 million.
- In the last 5 years, Madrigal Pharmaceuticals' EBIAT plummeted by 9187.08% in 2024 and then skyrocketed by 7217.82% in 2025.
- Over the past 5 years, Madrigal Pharmaceuticals' EBIAT (Quarter) stood at -$64.5 million in 2021, then crashed by 33.08% to -$85.9 million in 2022, then plummeted by 30.6% to -$112.2 million in 2023, then surged by 47.03% to -$59.4 million in 2024, then crashed by 92.16% to -$114.2 million in 2025.
- Its last three reported values are -$114.2 million in Q3 2025, -$42.3 million for Q2 2025, and -$73.2 million during Q1 2025.